



## ORAL PRESENTATIONS 1 to 46

November 16–18

- 1 **Evolutionary biology of endotoxin: from genomics to physiology**  
*Whitfield C. (Guelph, ONT, Canada)*
- 2 **Endotoxin signaling**  
*Golenbock D.T. (Worcester, MA, USA)*
- 3 **Remodeling of *Helicobacter pylori* LPS**  
*Tran A.X., Stead C.M., Trent M.S. (Johnson City, TN, USA)*
- 4 **Structure and function of PagP**  
*Bishop R.E. (Toronto, ONT, Canada)*
- 5 **Lipid A deacylation by PagL: regulation of TLR4 signaling**  
*Kawasaki K., Ernst R.K., Miller S.I. (Tokyo, Japan and Seattle, WA, USA)*
- 6 **Biological relevance of lipid A variation in *Yersinia* species**  
*Ernst R.K., Rebeil R., Miller S.I., Hinnebusch B.J. (Seattle, WA, and Hamilton, MT, USA)*
- 7 **Lipid-mediated resistance of Gram-negative bacteria against various pore-forming antimicrobial peptides (AMP)**  
*Gutsmann T., Hage S., David A., Roes S., Böbling A., Hammer M., Seydel U. (Borstel, Germany)*
- 8 **Molecules from eukaryotic algae possess LPS-like features but inhibit innate responses of mouse macrophages**  
*Pardy R.L. (Lincoln, NE, USA)*
- 9 **Endotoxin: physical requirements for cell activation**  
*Müller M., Lindner B., Schromm A.B., Seydel U. (Borstel, Germany)*
- 10 **Innate immune recognition of LPS by TLR4/MD-2**  
*Miyake K., Akashi S., Saitoh S., Fukase K. (Tokyo and Osaka, Japan)*
- 11 **Molecular basis of action of endotoxin agonists and antagonists**  
*Gioannini T.L., Teghanemt A., Zhang D.S., Apicella M., Weiss J.P. (Iowa City, IA, USA)*
- 12 **Structural interactions of LPS with MD-2 and neutralizing peptides**  
*Jerala R. (Ljubljana, Slovenia)*
- 13 **Structural determinants of Toll signaling: Spatzle and MD-2**  
*Gay N.J. (Cambridge, UK)*
- 14 **TRIF-related adaptor molecule (TRAM): a central player in LPS signaling**  
*Rowe D.C., Golenbock D.T., Fitzgerald K.A. (Worcester, MA, USA)*
- 15 **Identification of a cytosolic complex involving MyD88 and the transcription factor IRF-7 that triggers Toll-like receptor-induced IFN- $\alpha/\beta$  gene expression**  
*Honda K., Yanai H., Mizutani T., Negishi H., Ohba Y., Takaoka A., Taniguchi T. (Tokyo, Japan)*
- 16 **Detoxifying endotoxin: time, place and person**  
*Munford R.S. (Dallas, TX, USA)*
- 17 **Apolipoproteins modulate inflammatory responses to LPS in rodents and humans: implications for sepsis**  
*Rensen P.C.N., Berbée J.F.P., Schippers E.F., van der Hoogt C.C., van Diesel J.T., Bakker-Woudenberg I.A.J.M., Havekes L.M. (Leiden and Rotterdam, The Netherlands)*
- 18 **Endogenous apolipoprotein E (apoE) and ATP-binding cassette transporter (ABCA1) promote LPS efflux from macrophages**  
*Kitchens R.L., Thompson P.A. (Dallas, TX, USA)*
- 19 **Interactions between LPS and lung surfactant proteins**  
*Chaby R. (Orsay, France)*
- 20 **Toll-like receptor-mediated recognition by intestinal epithelial cells**  
*Hornef M. (Freiburg, Germany)*
- 21 **Negative regulation of TLR4 signaling by RP105**  
*Karp C.L., Divanovic S., Atabani S.F., Madan R., Trompette A., Belkaid Y., Golenbock D.T., Finberg R.W., Tarakhovskiy A., Vogel S.N., Kurt-Jones E.A. (Cincinnati, OH, Worcester, MA, New York, NY, Baltimore, MD, USA)*

- 276 *8th International Endotoxin Society Conference, Kyoto, Japan, 2004*
- 22 **Taming the humoral immune response to Gram-negative bacteria**  
*Lu M., Zhang M., Weiss J., Apicella M., Li X-H., Kitchens R., Yuan D., Munford R. (Dallas, TX and Iowa City, IA, USA)*
  - 23 **Non-LPS actions and targets of LBP (LPS binding protein)**  
*Schumann R.R. (Berlin, Germany)*
  - 24 **Evolution and integration of innate immune recognition systems: the Toll-like receptors**  
*Takeda K. (Kyushu, Japan)*
  - 25 **Peptidoglycan recognition and innate immunity**  
*Dziarski R. (Gary, IN, USA)*
  - 26 **Bacterial cell wall peptidoglycan: structure, function and metabolism**  
*Mengin-Lecreux D. (Orsay, France)*
  - 27 **Crystal structure of PGRP domain ( $\pm$  ligand)**  
*Mariuzza R. (Rockville, MD, USA)*
  - 28 **Nod1 and Nod2 are pattern-recognition molecules involved in peptidoglycan recognition**  
*Girardin S. (Paris, France)*
  - 29 **Structural and molecular determinants of pro-inflammatory properties of lipoteichoic acids**  
*Hartung T. (Konstanz, Germany)*
  - 30 **CD36 as a sensor of di-acylglycerides acting in conjunction with TLR2 and TLR6**  
*Hoebe K., Georgel P., Rutschmann S., Du X., Tabeta K., Mudd S., Sovath S., Shamel L., Hartung T., Zähringer U., Beutler B. (La Jolla, CA, USA and Borstel, Germany)*
  - 31 **Structure-activity relationships of bacterial lipopeptides with TLR2 heterodimers**  
*Shibata K-i. (Sapporo, Japan)*
  - 32 **Evolution and integration of innate immune systems from fruit flies to man: lessons and questions**  
*Reichhart J-M. (Strasbourg, France)*
  - 33 **Monomeric and polymeric Gram-negative peptidoglycan, but not purified LPS, stimulate the *Drosophila* IMD pathway**  
*Kaneko T., Golenbock D., Silverman N. (Worcester, MA, USA)*
  - 34 **Pattern recognition and lectin-complement pathway**  
*Fujita T. (Fukushima, Japan)*
  - 35 **Positive and negative regulation of Toll-like receptor signal transduction**  
*O'Neill L.A. (Dublin, Ireland)*
  - 36 **SOCS1 and SOCS3 are central regulators for macrophage and dendritic cell activation**  
*Yoshimura A., Nishinakamura H., Shiraishi H., Kinjyo I. (Fukuoka, Japan)*
  - 37 **Reprogramming of circulatory cells in sepsis and SIRS**  
*Cavaillon J.M., Adrie C., Fitting C., Beyaert R., Adib-Conquy M. (Paris and St Denis, France and Ghent, Belgium)*
  - 38 **TLRs and their adaptors in adjuvant immunotherapy for cancer**  
*Seya T., Matsumoto M., Akazawa T. (Sapporo, Japan)*
  - 39 **Genetic bases of host response to endotoxin and resistance to infection**  
*Vogel S.N. (Baltimore, MD, USA)*
  - 41 **Nod2: from human genetics to pathophysiology of Crohn's disease**  
*Chamaillard M. (Ann Arbor, MI, USA)*
  - 42 **Toll-like receptor 4 discriminates pathogens from commensals through pathogen specific recognition receptors**  
*Fischer H., Samuelsson P., Yamamoto M., Hoebe K., Tallqvist C., Beutler B., Akira S., Svanborg C. (Lund, Sweden, Osaka, Japan and La Jolla, CA, USA)*
  - 43 **Inherited human IRAK-4 deficiency and infectious diseases**  
*Puel A., Yang K., Jouanguy E., Picard C., Von Bernuth H., Ozinsky A., Casanova J-L. (Paris, France and Seattle, WA, USA)*
  - 44 **Short and Long-term suppression of atopic responses in the airways by TLR-4 agonists**  
*Baldrige J., Mossman S., Dillon D., Rudolph K., Barrett T., Persing D. (Seattle, WA, USA)*
  - 45 **The role and regulation of apoptosis in sepsis**  
*Ayala A., Wesche D.E., Lomas-Neira J.L., Perl M., Jones L., Chung C.S. (Providence, RI, USA)*
  - 46 **A systems approach to study of sepsis and innate immunity**  
*Ozinsky A. (Seattle, WA, USA)*